KYMRIAH

Phase 2Small molecule

MMasonic Cancer Center, University of Minnesota

KYMRIAH is one of 13 small molecule programs targeting CAR T Cell Therapy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CAR T Cell TherapyActive, not recruiting

CAR T Cell TherapyPhase 2

Active, not recruiting

Competition

Competitive Landscape

13 competitors in CAR T Cell Therapy

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 2

6 2

Cytoxan

BBaxter Healthcare Corporation

Phase 2

6 3

Kineret

SSwedish Orphan Biovitrum

Phase 2

1 4

CAR-T Cell Therapy

TThe First Affiliated Hospital of Soochow University

Phase 2

2 5

Cevostamab

Roche

Phase 2

1 6

Anti-BCMA-CAR-T

IInstitute of Hematology & Blood Diseases Hospital, China

Phase 2

1 7

CAR19TIF Cells

Novo Nordisk

Phase 2

1 8

Anti-CD19 CAR-T Cells

TThe Children's Hospital of Zhejiang University School of Medicine

Phase 1

1 9

YESCARTA

Incyte

Phase 2

1 10

Tecartus

HH. Lee Moffitt Cancer Center and Research Institute

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Active, not recruiting

CAR T Cell Therapy

NCT03642626

Clinical

Trials by Indication[1]

CAR T Cell Therapy1 trial

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Active, not recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03642626·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for KYMRIAH. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KYMRIAH compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KYMRIAH. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Masonic Cancer Center, University of Minnesota company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMasonic Cancer Center, University of Minnesota

KYMRIAH

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

CAR T Cell Therapy1 trial

References

Drug Info

Quick Facts

Related News